A Phase II Study of RO4929097 in Advanced Platinum Resistant Ovarian Cancer
Phase of Trial: Phase II
Latest Information Update: 30 May 2017
At a glance
- Drugs RG 4733 (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 23 Dec 2015 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 03 Sep 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.